{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
T2 Biosystems, Inc.
Is T2 Biosystems, Inc. overvalued or undervalued?
As of July 8, 2024, T2 Biosystems, Inc. is considered overvalued and has deteriorated to a "does not qualify" rating due to negative valuation ratios and a year-to-date return of -99.17%, significantly underperforming its peers and the S&P 500.
Is T2 Biosystems, Inc. technically bullish or bearish?
As of February 18, 2025, T2 Biosystems, Inc. shows a mildly bearish trend with mixed signals from moving averages and indicators, suggesting a weak bearish outlook but potential for improvement.
Who are in the management team of T2 Biosystems, Inc.?
As of March 2022, T2 Biosystems, Inc.'s management team includes Non-Executive Chairman John McDonough, CEO John Sperzel, Lead Independent Director John Cumming, and Independent Directors Seymour Liebman, Thierry Bernard, and David Elsbree. They oversee the company's strategic direction and operations.
What does T2 Biosystems, Inc. do?
T2 Biosystems, Inc. is an in vitro diagnostics company focused on pathogen detection and biomarker analysis, with a market cap of $3.65 million and quarterly net sales of $2 million but a net loss of $10 million as of September 2024.
How big is T2 Biosystems, Inc.?
As of Jun 18, T2 Biosystems, Inc. has a market capitalization of 3.65 million, with recent net sales of 7.68 million and a net profit of -42.95 million. The company's shareholder's funds were -28.04 million, and total assets amounted to 34.80 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
